UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

Clinical rheumatology, 2020-11, Vol.39 (11), p.3341-3352

2020

Volltextzugriff (PDF)

Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

Clinical rheumatology, 2020-11, Vol.39 (11), p.3527-3527

2020

Volltextzugriff (PDF)

A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis

Rheumatology and therapy., 2020-03, Vol.7 (1), p.149-163

2020

Volltextzugriff (PDF)

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

Annals of the rheumatic diseases, 2017-08, Vol.76 (8), p.1340-1347

2017

Volltextzugriff (PDF)

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

Annals of the rheumatic diseases, 2017-01, Vol.76 (1), p.88-95

2017

Volltextzugriff (PDF)

The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2016-09, Vol.68 (9), p.2163-2173

2016

Volltextzugriff (PDF)

A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis

The New England journal of medicine, 2023-05, Vol.388 (20), p.1853-1862

2023

Volltextzugriff (PDF)

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Annals of the rheumatic diseases, 2020-01, Vol.79 (1), p.123-131

2020

Volltextzugriff (PDF)

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

The Lancet (British edition), 2018-12, Vol.392 (10163), p.2441-2451

2018

Volltextzugriff (PDF)

The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double‐Blind, Placebo/Active‐Controlled, Dose‐Ranging Study

Arthritis & rheumatology (Hoboken, N.J.), 2015-10, Vol.67 (10), p.2591-2600

2015

Volltextzugriff (PDF)

Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

Arthritis & rheumatology (Hoboken, N.J.), 2019-02, Vol.71 (2), p.258-270

2019

Volltextzugriff (PDF)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Annals of the rheumatic diseases, 2015-02, Vol.74 (2), p.333-340

2015

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

The Lancet (British edition), 2013-08, Vol.382 (9894), p.780-789

2013

Volltextzugriff (PDF)

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

Annals of the rheumatic diseases, 2013-03, Vol.72 (3), p.337-344

2013

Volltextzugriff (PDF)

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)

Annals of the rheumatic diseases, 2021-08, Vol.80 (8), p.1022-1030

2021

Volltextzugriff (PDF)

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

Rheumatic & musculoskeletal diseases open, 2022-03, Vol.8 (1), p.e002110

2022

Volltextzugriff (PDF)

Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

The Lancet. Rheumatology, 2022-06, Vol.4 (6), p.e395-e406

2022

Volltextzugriff (PDF)

Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2

Rheumatology and therapy., 2021-12, Vol.8 (4), p.1827-1844

2021

Volltextzugriff (PDF)

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial

Annals of the rheumatic diseases, 2018-04, Vol.77 (4), p.495-499

2018

Volltextzugriff (PDF)

Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study

Rheumatology advances in practice, 2022, Vol.6 (2), p.rkac038-rkac038

2022

Volltextzugriff (PDF)

Safety and efficacy of baricitinib at 24weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Annals of the rheumatic diseases, 2015-02, Vol.74 (2), p.333-340

2015

Volltextzugriff (PDF)

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

Rheumatic & musculoskeletal diseases open, 2018, Vol.4 (1), p.e000662-e000662

2018

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Rheumatology
(17)
Science & Technology
(17)
Humans
(12)
Patients
(12)
Double-Blind Method
(11)
Adult
(10)
Female
(10)
Male
(10)
Middle Aged
(10)
Rheumatoid Arthritis
(10)
Treatment Outcome
(10)
Arthritis
(9)
Drug Dosages
(9)
Antirheumatic Agents - Therapeutic Use
(7)
Arthritis, Rheumatoid - Drug Therapy
(7)
Monoclonal Antibodies
(7)
Tumor Necrosis Factor-Tnf
(7)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(6)
Cytokines
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis

A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double‐Blind, Placebo/Active‐Controlled, Dose‐Ranging Study

Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial

Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study

Rheumatoid arthritis oral abstractsO01. Efficacy and Safety of Baricitinib Versus Placebo and Adalimumab in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Summary Results from the 52-Week Phase 3 RA-Beam Study

Rheumatoid arthritis oral abstractsO01. Efficacy and Safety of Baricitinib Versus Placebo and Adalimumab in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Summary Results from the 52-Week Phase 3 RA-Beam Study

Safety and efficacy of baricitinib at 24weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

Suchergebnisse filtern